Health
Novel nasal spray reduces viral replication by up to 96%: according to COVID-19 challenge study – BioPharma-Reporter.com
Ena Respiratory’s preventative nasal spray treatment could reach human trials within four months, following results from an animal study released today which showed the spray reduced COVID-19 replication by up to 96%.
The novel nasal spray, INNA-051, is being developed by Australian biotech Ena Respiratory. The company has published its animal study, led by Public Health Englands Deputy Director Professor Miles Carroll, on biomedical pre-publication research site medRxiv.
The researchers note that INNA-051 significantly reduced COVID-19 virus levels in the nose and throat. A nasal administration delivered once or twice a week could be used to prevent infection in at-risk populations and healthcare workers, s…
-
Noosa News11 hours agoExperts share tiny home warning as interest from young people soars
-
Noosa News17 hours agoKarenia cristata species source of toxins in SA’s algal bloom, scientists believe
-
General7 hours agoConvicted mushroom murderer Erin Patterson outlines her reasons to appeal
-
Noosa News10 hours agoExpert’s warning as tourists stunned by hundreds of sharks spotted close to shore at Moreton Island, Queensland